| 引用本文:毛楠1，郑韵恒1，周雨1，马欣1，樊均明1，2.肾痿方治疗慢性肾脏病3~5期非透析患者的临床疗效分析[J].世界中医药,2018,(11):. |
|
| 肾痿方治疗慢性肾脏病3~5期非透析患者的临床疗效分析 |
| Clinical Efficacy of Shenwei Formula in Treating Non-dialysis Patients with Chronic Kidney Disease in Stage 3-5 |
| 投稿时间：2018-07-11 |
| DOI：10.3969/j.issn.1673-7202.2018.11.036 |
| 中文关键词: 慢性肾脏病 肾痿方 中医证候积分 肾功能 |
| English Keywords:Chronic renal disease Shenwei Formula TCM syndrome integral Renal function |
| 基金项目:四川省医学科研青年创新项目(Q16016);四川省老年医学研究中心专项科研项目(SCLNZX201801);四川省科技厅-泸州市人民政府-泸州医学院2014年联合科研项目(14ZC0027) |
|
| 摘要点击次数: 815 |
| 全文下载次数: 1066 |
| 中文摘要: |
| 目的:观察肾痿方在治疗慢性肾脏病3~5期非透析患者中的临床疗效及安全性。方法:选取2016年1月至2017年6月成都医学院第一附属医院收治的慢性肾脏病3~5期非透析患者120例作为研究对象,随机分为对照组和观察组,每组60例,对照组给予肾衰宁胶囊和常规治疗,观察组给予肾痿方和常规治疗,比较2组临床疗效及治疗前后中医证候积分的变化;比较治疗前后血清尿素氮,血清肌酐、血浆白蛋白、血红蛋白和肾小球滤过率等指标的变化;观察患者服用肾痿方有无发生不良反应。结果:服药6个月后,观察组临床有效率达86.67%明显高于对照组的60%(P<0.05);2组治疗前各项指标比较,差异无统计学意义;治疗后观察组倦怠乏力、气短懒言、食少纳呆、畏寒肢冷、面色晦暗、腰膝酸软、肢体困重、恶心呕吐和腰痛等症状改善明显优于对照组及其治疗前(P<0.05);治疗后观察组血清尿素氮和血清肌酐水平明显低于对照组及其治疗前(P<0.05);肾小球滤过率、血红蛋白和血浆白蛋白水平高于对照组及其治疗前,差异有统计学意义(P<0.05);观察组不良反应发生率8.33%,对照组不良反应发生率5%,2组比较差异无统计学意义(P>0.05)。结论:肾痿方能够有效地延缓慢性肾脏病3~5期患者的肾功能下降,改善肾性贫血,缓解倦怠乏力、气短懒言、食少纳呆、肢体困重、恶心呕吐、腰痛等症状,且具有较好的临床安全性。 |
| English Summary: |
| To observe the clinical efficacy and safety of Shenwei Formula in treating non-dialysis patients with chronic kidney disease in stage 3-5.Methods:A total of 120 non-dialysis patients with chronic kidney disease in stage 3-5 were selected in the First Afliated Hospital of Chengdu Medical College from January 2016 to June 2017 as research object，and were randomly divided into control group and observation group，with 60 patients in each group.The control group was given Shenshuaining capsule and routine treatment.The observation group was given Shenwei Formula and routine treatment.The curative effect of the two groups and the TCM syndrome scores before and after the treatment were compared.The changes in serum urea nitrogen (blood urea nitrogen，BUN)，serum creatinine (serum creatinine，Scr) before and after treatment，the changes in estimated glomerular filtration rate (estimating glomerular filtration rate，eGFR)，plasma albumin，and hemoglobin levels，and the observation of renal impotence in patients were compared.The adverse reactions were observed.Results:After taking the medicine for 6 months，the clinical efficiency of the observation group reached 86.67%，which was significantly higher than that of the control group (60%)，and there was no difference between the two groups before treatment (P<0.05).After treatment，there was no significant difference in all indexes before treatment.After treatment，the symptoms of tired，shortness of breath，poor appetite，aversion to cold，cold limbs，darkish complexion，soreness and weakness of waist and knees，heavy body，nausea and vomiting，and low back pain of the observation group were significantly better than those in the control group and before the treatment (P<0.05)，and the level of BUN and Scr in the observation group was significantly lower than that of the control group and before the treatment (P<0.05).The levels of eGFR，Hb and ALB were higher than those of the control group and before the treatment (P<0.05).The incidence of adverse reactions in the observation group was 8.33%，and the control group was 5%.There was no significant difference between the two groups (P>0.05).Conclusion:Shenwei Formula can effectively retard the decreased of renal function in patients with stage 3-5 chronic kidney disease，improve renal anemia，relieve fatigue，shortness of breath，anorexia，nausea and vomiting，body pain and other symptoms，and has clinical safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
